Program
remimazolam tosylate
Also written as “Remimazolam Tosilate”, “Remimazolam Tosilate for Injection” and “Remimazolam Tosylate”.
Its studies are led by Jiangsu HengRui Medicine.
Furthest: phase 4, since Dec 6, 202315 company-led studies, 1 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Jiangsu HengRui Medicine | 151 open or running | phase 4since Dec 6, 2023 | Oct 22, 2013 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 22, 2013First study: phase 1 study in HealthyFirst studyNCT01970072 · 79 enrolled · China
- Feb 15, 2015Phase 2 study in General AnesthesiaNCT02406872 · 144 enrolled · China
- Aug 4, 2015Phase 1 study in AnesthesiaNCT03444480 · 8 enrolled · China
- Dec 22, 2016Phase 2 study in SedationNCT03003884 · 153 enrolled · China
- Sep 16, 2017Phase 3 study in SedationNCT03425474 · 378 enrolled · China
- Dec 16, 2018Phase 3 study in SedationNCT03779061 · 388 enrolled · China
- Apr 15, 2019Phase 3 study in Anesthesia for Elective Surgery PatientsNCT03921775 · 330 enrolled · China
- May 14, 2020Phase 3 study in SedationNCT04400201 · 330 enrolled · China
- Aug 11, 2021Phase 2 study in Local Anesthesia Assisted SedationNCT05015361 · 108 enrolled · China
- Nov 29, 2021Phase 2 study in Sedation in the ICUNCT05152303 · 60 enrolled · China
- Jun 13, 2023Phase 2 study in Sedation in the ICUNCT05913336 · 24 enrolled · China
- Dec 6, 20232 phase 4 studiesNCT06169995, NCT06216444
- Dec 28, 2023Phase 3 study in Sedation in the ICUNCT06222294 · 214 enrolled · China
- Jun 16, 2025Phase 3 study in Operative Sedation of PediatricNCT07036419 · 249 enrolled · China
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 15 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07036419Operative Sedation of Pediatric · China | 3 | Completed | May 27, 2026 | 249 |
| NCT06222294Sedation in the ICU · China | 3 | Completed | Aug 13, 2024 | 214 |
| NCT06216444Sedation in Non-intubated Diagnostic and Therapeutic Procedures · China | 4 | Not yet recruiting | Mar 2024 | 240 |
| NCT06169995Sedation in the Upper Gastrointestinal Endoscopy · China | 4 | Completed | Dec 15, 2023 | 31 |
| NCT05913336Sedation in the ICU · China | 2 | Completed | Mar 5, 2025 | 24 |
| NCT05152303Sedation in the ICU · China | 2 | Completed | Apr 2, 2023 | 60 |
| NCT05015361Local Anesthesia Assisted Sedation · China | 2 | Completed | Jun 18, 2021 | 108 |
| NCT04400201Sedation · China | 3 | Completed | Oct 28, 2020 | 330 |
| NCT03921775Anesthesia for Elective Surgery Patients · China | 3 | Completed | Dec 30, 2019 | 330 |
| NCT03779061Sedation · China | 3 | Completed | Sep 20, 2018 | 388 |
| NCT03425474Sedation · China | 3 | Completed | Nov 10, 2017 | 378 |
| NCT03003884Sedation · China | 2 | Completed | Mar 2017 | 153 |
| NCT03444480Anesthesia · China | 1 | Completed | Aug 16, 2014 | 8 |
| NCT02406872General Anesthesia · China | 2 | Completed | Aug 2015 | 144 |
| NCT01970072Healthy · China | 1 | Completed | Jun 20, 2014 | 79 |
How it is read
Names in the registry
- “Remimazolam Tosilate”, 12 entries
- “Remimazolam Tosilate for Injection”, 2 entries
- “Remimazolam Tosylate”, 2 entries
- “Remimazolam Tosilate for injection”, 1 entry
Conditions, from the studies’ own filings
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.